Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
Results
-
Notice concerning adoption of
[PDF 53KB]
International Financial Reporting Standards (IFRS) -
Organizational and Personnel Changes
[PDF 146KB] -
Chugai Pharma Manufacturing to Conclude an Agreement with Fujieda City
[PDF 349KB]
to Offer Help During Times of Disaster -
Co-Development and Co-Marketing Agreement for
[PDF 17KB]
the Glycoengineered Type II Anti-CD20 Monoclonal Antibody,
“GA101 (obinutuzumab)” -
Notice Concerning the Passing Away
[PDF 162KB]
of a Chugai Pharmaceutical Director -
ADACTA Study Showed ACTEMRA Improved Signs and Symptoms
[PDF 214KB]
of Rheumatoid Arthritis Significantly More Than Adalimumab as a
Single-Agent Therapy -
Eli Lilly Japan and Chugai to Terminate
[PDF 144KB]
Co-Marketing Agreement of “EVISTA® tablet 60mg,”
a Treatment for Osteoporosis in Postmenopausal Women -
Supply Plan of "Tamiflu®" Anti-influenza Drug for the 2012-2013 Season
[PDF 133KB] -
License Agreement of SGLT2 Inhibitor “CSG452” in Japan
[PDF 96KB] -
Chugai Presents an Anti-Cancer Charity
[PDF 200KB]
“WAHAHA HONPO Special Live Show” -
Chugai Succeeds in Establishing Stable Cell Lines of Cancer
[PDF 231KB]
Stem Cell for the First Time -
F. Hoffmann-La Roche Announces Third Quarter Sales 2012
[PDF 22KB] -
FDA Approves Expanded Indication for ACTEMRA®
[PDF 187KB]
in Rheumatoid Arthritis -
Anti-Cancer Agent “Avastin®,”
[PDF 177KB]
Application for Approval of Additional Indication of Ovarian Cancer -
Novel Concept for Treatment of Hemophilia A
[PDF 189KB]
Published in Nature Medicine -
Contribution of Para-transit Vehicles to Welfare Services
[PDF 224KB] -
Anti-Cancer Agent “Avastin®,”
[PDF 177KB]
Application for Approval of Additional Indication of
Recurrent Glioblastoma -
Resignation of a Director
[PDF 172KB] -
Synthetic Antibacterial Agent, Bactramin®
[PDF 117KB]
Approved for Additional Indication of
“Treatment and Prevention of Pneumocystis Pneumonia” -
Roche Reports Second Positive Study of RoACTEMRA Given by
[PDF 213KB]
Subcutaneous Injection to Patients with Rheumatoid Arthritis -
F. Hoffmann-La Roche Announces Second Quarter Sales 2012
[PDF 21KB] -
New Drug Application Filed for Ibandronate Sodium Hydrate Injection,
[PDF 19KB]
Bisphosphonate Antiresorptive Agent -
Opening of Chugai’s Research Subsidiary
[PDF 199KB]
“Chugai Pharmabody Research Pte. Ltd.” in Singapore -
Anti-Cancer Agent “Tarceva®,”
[PDF 170KB]
Application for Approval of Additional Indication of
Non-Small Cell Lung Cancer (First Line Therapy) -
Launch of an Orphan Drug, “Pulmozyme®,”
[PDF 366KB]
a Recombinant Human Deoxyribonuclease I (rhDNase) -
Roche’s RoACTEMRA
[PDF 194KB]
Improved Rheumatoid Arthritis Signs and Symptoms
Significantly More than Adalimumab as Single-Agent Therapy -
New Drug Application Filed for Anti-Cancer Agent “Pertuzumab”
[PDF 189KB]
for the Treatment of HER2-Positive Metastatic or Recurrent
Breast Cancer -
Chugai Renews its “Human Body System” Website
[PDF 162KB] -
Determination of Terms and Conditions of Stock Options (Stock Acquisition Rights)
[PDF 50KB] -
Roche Reports Positive Study of RoACTEMRA
[PDF 244KB]
Given by Subcutaneous Injection -
Issuance of Stock Options (Stock Acquisition Rights)
[PDF 79KB] -
F. Hoffmann-La Roche Announces First Quarter Sales 2012
[PDF 21KB] -
Chugai Establishes Endowed Course at Keio University
[PDF 150KB]
– “Health” related issues to be extracted and searched for solutions – -
Approval of an Orphan Drug, “Pulmozyme®,”
[PDF 243KB]
a Recombinant Human Deoxyribonuclease I (rhDNase) -
Roche’s RoACTEMRA Monotherapy Showed Superior Improvement in Rheumatoid Arthritis Signs and Symptoms Versus Adalimumab Monotherapy
[PDF 249KB] -
FDA Accepts Supplemental Biologics License Application Submitted for
[PDF 181KB]
ACTEMRA®, a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody,
Regarding Adult Rheumatoid Arthritis Indication -
Synthetic Antibacterial Agent, Bactramin®
[PDF 94KB]
Filed for Additional Indication By
“Application Based on Evidence in the Public Domain” -
Anti-Cancer Agent, Tarceva®
[PDF 173KB]
Condition for Approval (All Patients Surveillance) Partially Removed in Japan for
“Nonresectable Recurrent and Advanced Non-small Cell Lung Cancer
which is Aggravated Following Chemotherapy” -
Notice of Changes to Representative Directors
[PDF 50KB] -
Personnel Changes
[PDF 54KB] -
Organizational and Personnel Changes
[PDF 151KB] -
Notice of Partial Amendments to the Articles of Incorporation
[PDF 50KB] -
F. Hoffmann-La Roche Announces Financial Results for Fiscal 2011
[PDF 40KB]